Showing results (1-10 of 58) with videos related to
Sort By:
Pageof 6
HRB Open Research|February 1, 2020
Assessment of the understanding of informed consent including participants' experiences, and generation of a supplemental consent decision aid for Gestational Diabetes Mellitus (GDM) researchShubham Atal, Fidelma DunnePharmaceutical Medicine|June 15, 2020
IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy?Shubham Atal, Zeenat FatimaCurrent Drug Research Reviews|May 31, 2022
Molnupiravir in COVID-19: A Scoping ReviewShilpa Kaore, Shubham AtalJournal of Basic and Clinical Physiology and Pharmacology|November 14, 2015
Ulinastatin - a newer potential therapeutic option for multiple organ dysfunction syndromeSarjana S Atal, Shubham AtalJournal of Family Medicine and Primary Care|March 14, 2022
Continued use of azithromycin for mild COVID-19 in India: Evidence and implications?Shubham Atal, Saurav Misra, Sadasivam BalakrishnanBiodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 13, 2020
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?Shubham Atal, Zeenat Fatima, Sadasivam BalakrishnanJournal of Clinical Pharmacy and Therapeutics|February 19, 2020
Recent advances in targeted small-molecule inhibitor therapy for non-small-cell lung cancer-An updateShubham Atal, Pravin Asokan, Ratinder JhajGlobal Cardiology Science & Practice|January 11, 2021
Understanding the molecular-pharmaceutical basis of sartan recalls focusing on valsartanAvik Ray, Shubham Atal, Balakrishnan SadasivamCureus|April 15, 2024
Willingness to Pay (WTP) for Newer Treatment Options for Diabetes: A Study Among Patients at a Tertiary Care CentreShrutangi Vaidya, Shubham Atal, Rajnish JoshiJournal of Family Medicine and Primary Care|December 26, 2024
Which antidiabetic drugs do patients of T2DM prefer in India and why? A discrete choice experimentShrutangi Vaidya, Shubham Atal, Rajnish JoshiPageof 6